<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778763</url>
  </required_header>
  <id_info>
    <org_study_id>BL-612-BC1</org_study_id>
    <nct_id>NCT02778763</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis</brief_title>
  <official_title>Double Blind, Randomized, Placebo-controlled, Multicenter Pilot Study on Efficacy and Safety of CBLB612 Following Single Administration for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLab 612 LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cleveland BioLabs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioLab 612 LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety&#xD;
      of CBLB612 following single administration for neutropenia prophylaxis in breast cancer&#xD;
      patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of ANC &lt;1.0 x 103/μl (Grade 3-4)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of ANC &lt;0.5 x 103/μl (Grade 4)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum level of ANC decrease (nadir)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recovery of ANC level ≥1.5 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia (simultaneous drop of ANC &lt;0.5 x 103/μl and body temperature &gt;38.0°C)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation as measured by treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;50 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;25 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia &lt;10 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease of platelet level (nadir)</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet level recovery ≥75 x 103/μl</measure>
    <time_frame>Baseline to up to 38 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in comparison with baseline level CD34+ by FACS</measure>
    <time_frame>Baseline to up to 11 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in comparison with baseline level absolute reticulocyte count</measure>
    <time_frame>Baseline to up to 24 days after 1st the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of concentration of G-CSF by ELISA</measure>
    <time_frame>Baseline to up to 11 days after the 1st drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBLB612</intervention_name>
    <description>4 μg CBLB612 SQ</description>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>One injection of CBLB612 after Сhemo</arm_group_label>
    <arm_group_label>One injection of CBLB612 prior Сhemo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBS</other_name>
    <other_name>Phosphate buffer saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent for the study participation.&#xD;
&#xD;
          2. Women in the age above 18 years inclusively.&#xD;
&#xD;
          3. Patients with histologically proven diagnosis of breast cancer to which the 1-st cycle&#xD;
             of AC chemotherapy treatment is indicated (with 3-week interval).&#xD;
&#xD;
          4. ECOG Performance Status of 0-2.&#xD;
&#xD;
          5. Life expectancy ≥ 6 months.&#xD;
&#xD;
          6. Completion of all previous cancer therapies (including surgery, radiotherapy,&#xD;
             chemotherapy, immunotherapy or study therapy) not later than 4 weeks prior the CBLB612&#xD;
             study.&#xD;
&#xD;
          7. All acute toxic effects of any previous therapies &lt;Grade 1 prior the study, except for&#xD;
             alopecia and/or neurotoxicity (Grade 1 or 2 is allowed).&#xD;
&#xD;
          8. Adequate hematopoiesis function:&#xD;
&#xD;
               -  WBC ≥3.0 x 103/μl;&#xD;
&#xD;
               -  PTT ≥1.5 x 103/μl;&#xD;
&#xD;
               -  Platelets ≥75 x 103/μl;&#xD;
&#xD;
               -  Hemoglobin ≥10 g/dl.&#xD;
&#xD;
          9. Adequate hepatic function:&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x ULN;&#xD;
&#xD;
               -  ALT and AST ≤3 x ULN;&#xD;
&#xD;
               -  Alkaline phosphatase ≤2.5 x ULN.&#xD;
&#xD;
         10. Adequate renal function:&#xD;
&#xD;
               -  Creatinine ≤1.5 x ULN.&#xD;
&#xD;
         11. Adequate values of hemostasis system:&#xD;
&#xD;
               -  Prothrombin time;&#xD;
&#xD;
               -  ≤1.5 x ULN;&#xD;
&#xD;
               -  Activated partial thromboplastin time ≤1.5 x ULN;&#xD;
&#xD;
               -  INR ≤1.5 x ULN.&#xD;
&#xD;
         12. Adequate cardiac function which means&#xD;
&#xD;
               -  LVEF ≥45 based on ultrasonic examination of the heart or radionuclide&#xD;
                  angiography;&#xD;
&#xD;
               -  12-lead electrocardiogram (ECG) with normal tracing, non-clinically significant&#xD;
                  changes may occur that do not require medical intervention.&#xD;
&#xD;
         13. Negative test for serological infection markers:&#xD;
&#xD;
               -  Negative HIV-antibody test;&#xD;
&#xD;
               -  Negative test for hepatitis B surface antigen (HBsAg);&#xD;
&#xD;
               -  Negative test for hepatitis C virus antibodies or negative test for mRNA of&#xD;
                  hepatitis C virus;&#xD;
&#xD;
               -  Negative test for Treponema pallidum antibodies.&#xD;
&#xD;
         14. Negative pregnancy test.&#xD;
&#xD;
         15. Consent of a patient with preserved reproductive function to use effective&#xD;
             contraception method since screening up to at least 3 months after the study therapy.&#xD;
&#xD;
               -  e.g. intrauterine device, oral contraceptive, subcutaneous implant or&#xD;
                  double-barrier method (condom with contraceptive sponge or contraceptive vaginal&#xD;
                  suppository).&#xD;
&#xD;
         16. A patient shall be ready and able to meet the requirements of the study protocol and&#xD;
             have the opportunity to participate in the study throughout the scheduled period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rapidly progressing, clinically unstable breast cancer with present clinical signs of&#xD;
             cerebral or meningeal membrane metastases.&#xD;
&#xD;
          2. Specific contraindications or hypersensitivity data in relation to any of the&#xD;
             following drugs: doxorubicin, cyclophosphamide, CBLB612, anti-emetic agents&#xD;
             (aprepitant, palonosetron), anti-inflammatory drugs (including paracetamol and&#xD;
             aspirin), as well excipients of the abovementioned drug agents including polysorbate&#xD;
             80.&#xD;
&#xD;
          3. History of febrile neutropenia.&#xD;
&#xD;
          4. Presence of autoimmune disease.&#xD;
&#xD;
          5. Acute or chronic/relapsing inflammatory eye disease or any other significant eye&#xD;
             disorder.&#xD;
&#xD;
               -  patients with mild and moderate myopia or hypermetropia, or presbyopia may be&#xD;
                  enrolled to the study.&#xD;
&#xD;
          6. Pregnancy or breast feeding, refusal to use adequate contraception methods during the&#xD;
             study.&#xD;
&#xD;
          7. Signs of ongoing systemic bacterial, fungal or viral infectious disease or local&#xD;
             infection requiring treatment at the randomization.&#xD;
&#xD;
               -  patients with local fungal lesion of skin area or nail may be enrolled to the&#xD;
                  study.&#xD;
&#xD;
          8. Systemic antibiotic therapy during up to 72 hours prior the randomization.&#xD;
&#xD;
          9. Previous radiotherapy of ≥30% of bone marrow.&#xD;
&#xD;
         10. Surgery or chemotherapy or experimental drug therapy within 4 weeks prior&#xD;
             randomization.&#xD;
&#xD;
         11. Transplantation of bone marrow or peripheral blood precursor cells.&#xD;
&#xD;
         12. Intake of more than 10 portions of alcoholic beverages per week or anamnestic data on&#xD;
             alcoholism, narcomania, drug abuse.&#xD;
&#xD;
               -  one portion of alcoholic beverage is 250 ml of beer, 125 ml of wine or 30 ml of&#xD;
                  strong alcoholic beverage.&#xD;
&#xD;
         13. Current immunosuppressant therapy including systemic corticosteroid therapy.&#xD;
&#xD;
         14. Clinically significant abnormal vital signs, results of laboratory and instrumental&#xD;
             tests, based on the investigator assessment.&#xD;
&#xD;
         15. Any disease, condition, organ dysfunction or central nervous system disorder of the&#xD;
             intake of narcotic drugs which, according to the investigator, may affect ability to&#xD;
             participate in the study or hinder assessment of study results.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei A. Tiuliandin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Russian Oncological Research Center named after N. N. Blokhin&quot; of the Russian Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleksei G. Manikhas, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.-Petersburg State Budgetary Healtcare Institution &quot;City Clinical Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitrii A. Krasnozhon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budgetary Healtcare Institution &quot;Leningrad Region Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruslan M. Paltuev, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-State Healtcare Institution &quot;Road Clinical Hospital of Open Joint Stock Company Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia V. Fadeeva, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Healtcare Institution &quot;Chelyabinsk Regional Clinical Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roman S. Ponomarev, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Region Budgetary Healtcare Institution &quot;Murmansk Region Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <link>
    <url>http://www.cbiolabs.com/cblb612</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>TLR2</keyword>
  <keyword>Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

